Company Description

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer.

The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors.

It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors.

The company was founded in 1996 and is based in Carlsbad, California.

Qualigen Therapeutics, Inc.

Country	United States
Founded	1996
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Kevin Richardson

Contact Details

Address: 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 United States
Phone	760 452 8111
Website	qlgntx.com

Stock Details

Ticker Symbol	QLGN
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001460702
CUSIP Number	74754R103
ISIN Number	US74754R3012
Employer ID	26-3474527
SIC Code	2834

Key Executives

Name	Position
Kevin A. Richardson II	Interim Chief Executive Officer, Interim Chief Financial Officer, Chief Accounting Officer and Chairman of the Board
Robert W. Campbell Becher	President and Director
Michael S. Poirier	Chief Operating Officer
Christopher L. Lotz	Vice President of Finance and Corporate Secretary

Latest SEC Filings

Date	Type	Title
Aug 13, 2025	D	Notice of Exempt Offering of Securities
Aug 7, 2025	SCHEDULE 13G/A	Filing
Jul 28, 2025	8-K	Current Report
Jul 28, 2025	8-K	Current Report
Jul 21, 2025	10-Q	Quarterly Report
Jul 16, 2025	8-K	Current Report
Jun 30, 2025	10-K	Annual Report
Jun 24, 2025	8-K	Current Report
May 19, 2025	8-K	Current Report
May 1, 2025	8-K	Current Report

View All SEC Filings